A US‑based electrical stimulation system shows promise for severe restless legs syndrome and could be launched in Britain soon.
Restless legs syndrome (RLS) is a neurological condition that pulls millions of people into nightly bouts of uncomfortable sensations and an irresistible urge to move the limbs, often leaving them exhausted for the day ahead.
Typical management relies on lifestyle tweaks and medication, yet many patients still endure disruptive symptoms and experience troublesome side-effects such as dopamine-agonist-induced gambling urges, heightened sexual drive or even suicidal thoughts.
Understanding restless legs syndrome and its treatment gaps
The disorder affects up to one in ten individuals, with a higher prevalence among women. The hallmark is a crawling or tingling feeling that intensifies at rest, especially after dark, prompting the patient to walk or stretch in an attempt to obtain relief.
The exact trigger remains elusive, although research points toward abnormal dopamine signaling in the brain and possible iron deficiency in central nervous tissue.
First-line advice focuses on reducing caffeine and alcohol, correcting iron deficiency and establishing consistent sleep hygiene.
When these measures fall short, physicians commonly prescribe dopamine agonists, gabapentin-type drugs or low-dose opioids. Long-term use of dopamine agents can lead to a phenomenon called augmentation where symptoms start earlier in the day and become more severe, prompting clinicians to seek alternatives.
How the Nidra electrical stimulation system works and what trials show
The newly marketed device, branded Nidra mimics the natural relief that many sufferers feel after walking. Small, flexible bands are placed just below the knees and deliver mild electrical pulses to the peripheral nerves for about 30 minutes while the patient lies in bed. By activating the same neural pathways involved in leg movement, the system provides a sensation comparable to a brief walk without the need to actually get up.
Clinical evidence
A recent multi-center study enrolled 232 participants whose RLS remained uncontrolled despite medication. After using the device during flare-ups, the average number of symptomatic days per week dropped from 6.1 to 4.8, and the 4 points. Nearly 80 % of users achieved what clinicians define as a clinically meaningful benefit and about 20 % were able to taper their existing drugs without a resurgence of symptoms. Reported adverse events were mild, consisting mainly of skin irritation or brief discomfort at the electrode sites.
While the trial lacked a placebo arm, the magnitude of improvement and the rapid onset of relief—most users reported noticeable effects within 30 minutes—support the device’s potential as a non-drug therapeutic option. Over 6,500 individuals in the United States have already purchased the system, which retails for roughly £6,000.
Potential arrival in the UK and what patients say
The manufacturer, Noctrix Health, confirmed ongoing discussions with British regulators about market entry. If approved, the device could be accessed via specialist clinics initially, with the long-term goal of NHS prescription, according to the company’s chief scientific officer.
Patient testimonies from the US underline the life-changing impact of the technology. One longtime sufferer described a three-week Mediterranean holiday finally enjoyed without nightly awakenings, calling the device “the best thing that has happened to me in ten years.” Others report mixed outcomes, noting that the system often works best when combined with existing medication rather than as a sole therapy.
Until the product becomes available locally, clinicians advise patients to verify iron levels, engage in regular aerobic exercise, limit caffeine and alcohol, and discuss any medication that might exacerbate RLS with their GP. Emerging alternatives such as vibrating pads and compression wraps exist, but robust evidence supporting their efficacy remains limited.
